# Study Of GW679769 In Major Depressive Disorder

> **NCT00102492** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 356 (actual)

## Conditions studied

- Depressive Disorder, Major
- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** GW679769

## Key facts

- **NCT ID:** NCT00102492
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102492, "Study Of GW679769 In Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00102492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*